This technology is a pharmacological method for preventing and treating right ventricular failure.
Right ventricular (RV) dysfunction is associated with the worst outcomes for patients with either heart failure or pulmonary hypertension. This condition is difficult to diagnose due to the nonspecific nature of the symptoms. Furthermore, there are currently no therapies to prevent or treat RV failure.
This technology uses a weighted gene co-expression network to identify genes correlated with RV failure and can be used to diagnose patients at risk for cardiopulmonary disease. In vitro models of heart failure in combination with gene suppression studies offer a potential physiological explanation for RV failure, identifying therapeutic targets that specifically regulate molecular mechanisms underlying this condition. To prevent and treat RVF, this technology uses pharmacological tools, including CRISPR gene editing technology, to modulate the expression of RVF-associated genes. Additionally, by detecting and measuring expression levels of these genes, this technology allows for monitoring, prognostics and treatment of RV failure.
This technology has been validated with RNA silencing in rat cardiomyocytes.
IR CU18328
Licensing Contact: Jerry Kokoshka
